Business Context and Reporting Period
This Form 8-K is a current report filed by Cerecor Inc. (noted as Avalo Therapeutics, Inc. in metadata) on September 21, 2016. The filing discloses the completion of patient enrollment in a Phase 2 clinical trial for the company's investigational drug, CERC-301.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial milestones and does not contain financial statements or performance metrics.
Material Changes
The primary material event reported is the completion of patient enrollment in the Phase 2 clinical trial (Clin301-203) evaluating CERC-301 as an oral, adjunctive treatment for major depressive disorder. No financial changes versus prior periods are disclosed in this document.
Guidance, Outlook, and Risks
- Outlook: The Company expects to report top-line data from the Phase 2 trial in November 2016.
- Study Objective: The primary objective is to evaluate the antidepressant effect of CERC-301 compared to placebo.
- Regulatory Note: The information provided in this Item 7.01 and the attached press release is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it subject to the liabilities of that Section.
Investor Verification Checklist
- Verify the expected release date of top-line data (November 2016) for the CERC-301 Phase 2 trial.
- Confirm the specific study design and primary endpoints for trial Clin301-203 in the attached press release (Exhibit 99.1).
- Review subsequent filings for the actual trial results once released.
- Note that this filing contains no financial data; refer to the most recent 10-Q or 10-K for financial health metrics.